Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the clarification; however I thought unless you sell subsequently it is not construed as profiting from insider news. My misunderstanding then..
Haven't seen any big insider buys yet; even Dr. Cox hasn't brought any below 0.5 which only tells me one thing...RS is on the cards with no partnership in sight.
Last cc, did he not indicate 'early' discussions started ? Such 'early' discussions don't get done in a month or two.
On the flip side, anyone knows how well the enrollment is going for the DIC P2 trials ? Might give some clue..
I see the writing on the wall....
GTCB going bankrupt after eventual delisting...
Just sold out my 50K at 50% loss..
Dew's READMEFIRST and all the hardwork he has done so far will not turn this POS around as long as Cox is at helm.
We will be south of 10cents by end of June.
I heard when the chop comes, the pain doesn't last long but I might be rolling my eyes with head on the ground for minute or two...who knows..LOL
Our Past has been better than the future, for sure...
http://journals.aol.com/hilaryonstocks/hilaryonstocks/entries/2006/06/15/gtc-biotherapeutics-nasdaq-gtcbmilk-it-for-all-it-is-worth/1350
All the authoritative posts regarding GTCB potential is doing squat to the PPS while Dr Cox & his gang continue to milk the goats dry.
We are just bunch of goats (no pun intended) waiting for eventual slaughter
How come we still don't see any insider activity if a major deal is going to be announced by end of June ?
I suspect the insiders have been doing some buying today
IMHO, much as this board articulates very well common shareholder's concerns, we haven't been able to pose or influence meaningful questions during CC.
One analyst continues to dick around in these CC calls, god knows, on behalf of who (shareholders).
No wonder GTCB fatcats can continue to get away with impunity.
Let's see if any of these insiders have been buying post-cc.
Well, if you take into account the GTCB fatcats' vacations to bermuda, they are doing best they can..LOL
Actually it is 19.99 in 5 easy installments
I had a dream...yes..dreamed this morning of PR from GTCB related to partnership on the same morning of their earnings announcement...
Could it happen ?
I think 90 days are over for the waiting period to see any antibodies develop for Atryn post-trial period. While no news is a good news (no surprise here based on EU trials), still GTCB could have released a PR to this effect to formally conclude the trial analysis.
This would have put public more at ease on adoption worries related to transgenic drugs.
Is Toms Newberry demoted 'again' ? His title now says only Corporate Communications and no additional Gov. Relations
Regardless of their partnership news, we got to hear their financial condition more closely...can they pull this off until DIC Phase 2 trials are out without further dilution...
I hate to say this...but I think we will never see > $1 again...the patents that GTCB holds do not interest big pharmas whatsoever.
The current GTCB doesn't have what it takes to engage big partner ; all they have added is getting more fatcats on their payrolls with nothing to show.
With no deal so far, GTCB is on the path for RS for sure..
I don't think any viable partner (IF there is one) is that stupid to pay more than what the recent investor did which is not going to help GTCB get thru next few months let alone until DIC P2 trial results come out.
The goats better start looking for greener pastures..
I won't give much credit to Newberry's ramblings...we would hae seen decent jump in the volume/pps by now if indeed the partnership is in the late stage and the terms are favorable to GTC.
Unless of course, the 'distant cousins' are all on long vacation and there is no one to take the call on the other end, if you know what I mean...
Interesting take on Buffett and Soros strategy...not long before GTCB comes on their radar as cheap & mass production platform...
http://finance.yahoo.com/tech-ticker/article/12050/Buffett-Soros-Betting-on-Biotech-'End-of-the-World'-Plays?tickers=GSK,SNY,MAPP,SVNT,JNJ,GENZ,BRK-B
To say 'couple of weeks' and nothing so far on partnership is really a shame on the GTCB management.
Anyone thinks we can hit $20 pps in couple of years time without RS ? TIA
Sometime I wonder...what would it be like to just walk in into their nice office and ask them point blank, the same question..
Did anybody notice the 1 yr target is back at $4 a share ? It was $2.50 last week. Some quirk in Yahoo update, perhaps ?
If RS is a possibility then why the recent investor plunked in 6 million bucks ?
I still think a meaningful partnership is going to happen soon.
Didn't Dr. Cox say, it's matter of weeks in last CC ?
Dew, I saw your post in Nuvello board in 2006 when the P3 failed for the first time and was drawn to GTCB after sending you a PM.
It's year and half now and GTCB turning out to be another Nuvello for different reasons...
I lost my shirt in Nuvello and now might loose my pants too..
With top management selling for scraps, it is more likely that the so called institutional investor shorted into the spikes before the private placement knowing very well that they can cover with the private placement
These dogs should be shot after letting them loose in hot desert road with no water
I agree definitely on the opportunity this presents. I did doubled up my holdings last two days.
I still hope we will get good analyst coverage post-partnership news.
With good upbeat CC and more optimistic look now, I wonder how soon the analysts will issue the upgrades, if at all.
Part of the management failure is not able to connect with analyst community in spite of all progress the company has made.
I am bit puzzled by the recent PPS action especially after the new institutional investor scooped shares at 0.87. Let's forget the warrants for a moment, as it is not worth the paper it is written on for the next 7 years. Who knows what will happen 7 years from now.
I would think this institutional investor who plucked in ~$6 Mil surely would have done enough DD on GTCB's 2008 financial prospects.
They really had to be dumb to get a 35% hair cut in less than a month
Seems to me the sell off is overreaction to the auditor's comments.
LEO Pharma A/S, GTC’s marketing and development partner for ATryn® in Europe, Canada, and the Middle East, launched the product in the approved indication for hereditary deficient patients undergoing surgical procedures. Pricing was established in November in the United Kingdom and subsequently in Ireland and Greece. Commercial availability is being expanded as pricing is further established on a country-by-country basis.
As LEO expands into other countries in 2008, there might be possibility of providing cash into 4Q'08 or around the time DIC P2 results would be out.
All assuming no partnership until then but hopefully that's unlikely
Definite insider news has leaded out.
Seems more & more like, r. Cox and his "Phd's" are wolfs in hiding among the goats.
If we don't hear anything substantial on thursday's CC, I would be very disappointed.
Mary Gray was brought in specifically to make the wall street deals and she just converted GTCB shares into coupons for pennies.
The financial environment being difficult as it is, the least GTCB can share with the shareholders is
- how are we doing on Atryn sales in Europe ?
- any viable steps to avoid de-listing other othen reverse split
- engaging more aggressively wall street analysts to get 'their' buy-in on recommendations
I hope it is not the same old 'Phd' talk on transgenics that we all know it works.
Now that all enrollment requirements are complete, when likley the partnership announcements may be made ? TIA
I still think partnership is on the near horizon.
We should see $3 by end of June.
Dew,
Regardless who owns the goat herd, if GTCB owns the patents (on producing proteins using transgenic mammals), doesn't then imply that PIP should pay royalty to GTCB ?
TIA
I bet Dr. Lawton's single focus is on his 401k until retirement and may be take few goats on the way out for BBQ..
One would wonder what this guy does to earn his fat salary
Agree..they could that on 7/14th if they have to.
However if we don't see any partnership news by May end, we know what's coming down the road.
'I was told that they would consider a reverse stock split in order to meet NASDAQ requirements.
I doubt their PR would have shared such a news before if at all, it happens.
Next few months is a key.
Expect the news flow to positively impact the PPS.
Atryn potential use in antithrombin deficiency in patients undergoing coronary artery bypass surgeries which is potentially a $150 million to $200 million-a-year market, might draw a partner soon to the table plus for other indications such as burns..
Remember, Dr. Cox comments says 'multiple parties'
GTCB has until July 15 '08 to comply with Nasdaq requirement...so plenty of time.
I am upbeat after reading Dr. Cox comments in a journal that someone posted (thanks) on this board earlier today.
All in all I still expect pps > $2 by end of this quarter.
Can anyone care to comment....TIA
Why would this new (or one of the current ones) institutional investor would pluck in 6mil of their money to see GTCB value destroyed ?
As Dew correctly pointed out, the current environment is worst the markets have seen to raise money.
So whoever came up with 6mill should have analyzed GTCB potential atleast as carefully (if not more) as many knowledgeable longs in this board.
GTCB Fatcats...Total Cash Comp data from 2004..no wonder, with this kind of comp year after year, who cares about shareholder value..
Name & Title Base
Pay Bonus Total TCC
Geoffrey F. Cox
Chairman Chief Executive Officer and President
$428,134 $94,100 $522,234
John B. Green
Senior Vice President Chief Financial Officer and Treasurer
$275,197 $46,170 $321,367
Harry M. Meade
Senior Vice President Research and Development
$268,053 $44,184 $312,237
Gregory F. Liposky
Senior Vice President Operations
$253,662 $44,370 $298,032
Daniel S. Woloshen
Senior Vice President and General Counsel
$233,412 $35,724 $269,136